CA
NZ
UK
AU
IND
US
Health care was one of only three S&P 500 sectors to finish higher on Monday, September 28, on a day that brought an upgrade for Teleflex (NYSE:TFX), a big licensing deal at Merck (NYSE:MRK) and a blockbuster session for biotech.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT), a penny stock, closed down 31.14% at $1.15 on Monday, September 28, 2026. The clinical-stage biotech recently listed on Nasdaq and has been advancing its Nu-3 program.
Kodiak Sciences (NASDAQ:KOD) closed up 177.96% at $89.92 on Monday, September 28, 2026. The clinical-stage retinal disease company reported positive topline results from its pivotal Phase 3 DAYBREAK study.
● Onconetix (ONCO) traded near $1.20, up about 16.5%, at 1:06 p.m. Eastern on Monday, according to a movers list.
● SL Science Holding (SLBT) closed at $1.93 on Monday, up 22.93% from $1.57, one of the Nasdaq's notable risers.
● YD Bio is a Taiwan-based biotech company working on methylation-based cancer diagnostics, and its shares trade on the Nasdaq.
Definium Therapeutics (NASDAQ:DFTX) was among the gainers in US markets on Monday, September 28, 2026, closing the session up 6.19% at $38.41. The company is a clinical-stage biotechnology company that is relatively recently public and lightly followed.
● Decoy Therapeutics (DCOY) closed at $2.31 on Monday, down 25.24% from $3.09, a steep one-day loss for the small biotech.
Decoy Therapeutics (NASDAQ:DCOY), a penny stock, was among the notable decliners in US markets on Monday, September 28, 2026, closing the session down 25.24% at $2.31. The small clinical-stage biotechnology company trades at a low absolute price with limited float.
● Merck (MRK) closed at $148.69 on Monday, essentially flat from $148.78, as theDow Jones Industrial Averagefell 347.11 points.
Please wait processing your request...